Jones Day (Washington)

Geoffrey D. Oliver

Jones Day (Washington)

Geoffrey Oliver is partner at Jones Day (Washington). His practice focuses on antitrust matters, with emphasis on government merger and conduct investigations and on litigation and counseling with respect to matters involving antitrust and patent law. He counsels high-tech and manufacturing companies in the computer, semiconductor, consumer electronics, satellite, defense, pharmaceutical, health care, and medical devices industries. Mr. Oliver co-coordinates the firm’s practice involving application of antitrust law to issues involving intellectual property. From 1998 to 2007, Mr. Oliver held various positions in the Federal Trade Commission’s Bureau of Competition, including Assistant Director responsible for the Anticompetitive Practices Division. During his tenure at the FTC, he supervised numerous nonpublic investigations and litigated cases in both the FTC’s Part III administrative proceedings and federal court. He was lead counsel on In re Rambus Inc. and played substantial roles on litigation teams for In re Hoechst Marion Roussel, Inc. et al., In re Intel Corp., and FTC v. Tenet Healthcare Corp. In addition to his enforcement responsibilities at the FTC, he participated in various policy initiatives involving standard-setting, intellectual property, and other issues. Before joining the FTC, Mr. Oliver spent ten years in private practice in Washington, D.C. and Brussels, Belgium. Mr. Oliver has written on antitrust enforcement topics and has spoken on antitrust and intellectual property issues in the United States and abroad. He currently serves on the board of editors of the ABA’s Antitrust magazine.


Auteurs associés

Jones Day (Paris)
Jones Day (Paris)
Jones Day (London)
Jones Day (Melbourne)
Jones Day (Washington)


7251 Bulletin

Peter J. Wang, Yizhe Zhang, Dr. Qiang Xue, Geoffrey D. Oliver, Alexandre G. Verheyden, Haifeng Huang The Chinese State Administration for Market Regulation publishes anti-monopoly guidelines on intellectual property


In August 2020, the Anti-Monopoly Bureau of China’s State Administration for Market Regulation released four long-awaited sets of anti-monopoly guidelines addressing issues relating to leniency, commitments, the automobile industry, and intellectual property rights. The subjects of this White (...)

Michael H. Knight, Geoffrey D. Oliver, Larissa C. Bergin The US Court of Appeals for the Third Circuit limits the FTC’s ability to seek damages for past conduct in a pharmaceutical patent abuse case (Shire Viropharma)


In Short The Situation : The United States Court of Appeals for the Third Circuit ruled that the FTC could not recover past profits under FTC Act Section 13(b) if the alleged violation occurred in the past and the defendant was not "violating" or "about to violate" the law. The Impact : (...)

Geoffrey D. Oliver, Kathryn Fenton, Matt Evans, Michelle Fischer, Peter J. Wang The US FTC and DOJ publish the proposed antitrust guidelines for international enforcement and cooperation


The Federal Trade Commission and the Department of Justice have published for public comment proposed Antitrust Guidelines for International Enforcement and Cooperation ("2016 Proposed Guidelines"). This would be the third iteration of international enforcement guidelines, following the (...)

Bevin M.B. Newman, Geoffrey D. Oliver, Michael Sennett The Court of Appeal for the District of Columbia rejects a challenge to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer all commercially significant rights (PhRMA)


The D.C. Circuit has rejected a challenge by the Pharmaceutical Research and Manufacturers of America ("PhRMA") to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer "all commercially significant rights." The rule, adopted in 2013, (...)

Geoffrey D. Oliver, Kevin D. McDonald, Michelle Fischer The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical)


The U.S. Court of Appeals for the Federal Circuit has remanded for further consideration antitrust claims accusing a patent holder of filing a sham infringement suit and a sham citizen petition with the Federal Drug Administration. The case is Tyco Healthcare Group LP v. Mutual Pharmaceutical (...)

Craig A. Waldman, David Wales, Geoffrey D. Oliver The US FTC announces an unusual proposed consent agreement to resolve unprecedented allegations on enforcement of standards-essential patents (Bosch / SPX)


The U.S. Federal Trade Commission this week announced a highly unusual proposed consent agreement reached with Robert Bosch GmbH ("Bosch") that permits Bosch’s acquisition of SPX Service Solutions U.S. LLC ("SPX Service Solutions") from SPX Corporation ("SPX") to proceed. More significantly, (...)

David Wales, Geoffrey D. Oliver, Michael H. Knight The US FTC sues to undo completed acquisition in the healthcare industry approved by the Bankruptcy Court (LabCorp / Westcliff)


The Federal Trade Commission has filed an administrative lawsuit seeking to undo Laboratory Corporation of America’s (« LabCorp ») acquisition of Westcliff Medical Laboratories, Inc. (« Westcliff »). According to the agency’s December 1 complaint, the merger will substantially lessen (...)

Geoffrey D. Oliver, Michael H. Knight, Toby G. Singer The US District Court for the District of Minnesota dismisses the US FTC complaint seeking divestiture and disgorgement remedy in consummated acquisition in the healthcare industry (Lundbeck)


In a decision that was filed under seal in late August but released publicly just last week, the U.S. District Court for the District of Minnesota dismissed with prejudice the complaint filed by the Federal Trade Commission (FTC) and the State of Minnesota challenging the already-consummated (...)

David M. Maiorana, Geoffrey D. Oliver, Kenneth R. Adamo, Michelle Fischer The US Court of Appeals for the Federal Circuit limits patent misuse doctrine and distinguishes it from antitrust violation (Princo)


The U.S. Court of Appeals for the Federal Circuit issued an en banc decision with significant implications for the doctrine of patent misuse. The decision issued last week overturns part of a Federal Circuit panel decision last year holding that Philips may have committed patent misuse by (...)

6928 Revue

Assimakis Komninos, Florence Ninane, Francesco Rosati, Geoffrey D. Oliver, Hendrick Bourgeois, Ioannis Lianos, James Killick, Johanne Peyre, Niamh McCarthy, Philippe Choné The EU guidance on exclusionary abuses : A step forward or a missed opportunity ?


What does the Commission’s recent Communication on enforcement of Article 82 EC mean for companies ? Does it make enforcement more predictable ? Does the greater use of economic concepts reduce the risk that intense competition on the merits by the part of a dominant firm will be considered (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message